What this is
- How it works
- How it works isn't classified yet
- Tested for
- Strictures Due to Crohn's Disease
- Main trialPhase 2
- “Crohn's disease (CD) is chronic inflammatory bowel disease where any part of the Gastrointestinal (GI) tract can become inflamed and develop fibrotic strictures. Intestinal strictures cause abdominal distension, cramping, dietary restrictions, nausea, vomiting, abdominal pain, and postprandial abdominal pain, which significantly impact patient quality of life. Rho-associated coiled-coil kinase (ROCK) family of proteins including ROCK1 and ROCK2 have been shown to play an important role in these fibrotic strictures. The investigational agent, RXC008, is an inhibitor of the activity of ROCK1…”In the company’s words, NCT07832435 on ClinicalTrials.gov
- Other names
- High Dose · Low Dose
Other drugs for Strictures Due to Crohn's Disease
- ProTractX3 TTS DCBGIE Medical · Phase 3
- FGF-1Venturis Therapeutics, Inc. · Phase 1/2
Coming up1
- 31 Aug 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 31 Aug 2028 | A Phase 2, Placebo-Controlled Study of Oral RXC008 for Crohn's Strictures |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026